University Hospital for Tumours of Zagreb Trials - Revision history

Lucas: Update categories.

2025-12-02T14:01:20Z

Update categories.

← Older revision		Revision as of 14:01, 2 December 2025
Line 1:		Line 1:
	{{forresearchers}}		<span style="display:none">forresearchers</span>
	{{forpatients}}		<span style="display:none">forpatients</span>
	{{forproviders}}		<span style="display:none">forproviders</span>
	{{croatiacountry}}		<span style="display:none">croatiacountry</span>
	{{hospital}}		<span style="display:none">hospital</span>
	{{cancer center}}		<span style="display:none">cancer center</span>
	Go back to [[University Hospital for Tumours of Zagreb]] page		Go back to [[University Hospital for Tumours of Zagreb]] page

Line 72:		Line 72:
	'''Recruitment Status''': ACTIVE_NOT_RECRUITING		'''Recruitment Status''': ACTIVE_NOT_RECRUITING
	'''Condition''': Muscle Invasive Bladder Cancer		'''Condition''': Muscle Invasive Bladder Cancer
			<span style="display:none">hasTrialTitle::Controlled Study of Rigosertib Versus Physician’s Choice of Treatment in MDS Patients After Failure of an HMA</span>
			<span style="display:none">hasTrialTitle::A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)</span>
			<span style="display:none">hasTrialTitle::An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting</span>
			<span style="display:none">hasTrialTitle::Study of Paclitaxel in Patients With Ovarian Cancer</span>
			<span style="display:none">hasTrialTitle::Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)</span>
			<span style="display:none">hasTrialTitle::Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)</span>

Francine at 19:42, 1 December 2025

2025-12-01T19:42:09Z

← Older revision		Revision as of 19:42, 1 December 2025
Line 2:		Line 2:
	{{forpatients}}		{{forpatients}}
	{{forproviders}}		{{forproviders}}
	{{~~croatia~~}}		{{croatiacountry}}
	{{hospital}}		{{hospital}}
	{{cancer center}}		{{cancer center}}

Victor at 18:42, 6 November 2024

2024-11-06T18:42:06Z

← Older revision		Revision as of 18:42, 6 November 2024
Line 1:		Line 1:
	{{forresearchers}} {{forpatients}} {{forproviders}} {{croatia}}		{{forresearchers}}
			{{forpatients}}
			{{forproviders}}
			{{croatia}}
			{{hospital}}
			{{cancer center}}
	Go back to [[University Hospital for Tumours of Zagreb]] page		Go back to [[University Hospital for Tumours of Zagreb]] page

Victor at 22:47, 5 November 2024

2024-11-05T22:47:12Z

← Older revision		Revision as of 22:47, 5 November 2024
Line 1:		Line 1:
	{{forresearchers}} {{forpatients}} {{forproviders}}		{{forresearchers}} {{forpatients}} {{forproviders}} {{croatia}}
	Go back to [[University Hospital for Tumours of Zagreb]] page		Go back to [[University Hospital for Tumours of Zagreb]] page

Victor: Victor moved page University Hospital for Tumors of Zagreb Trials to University Hospital for Tumours of Zagreb Trials

2024-08-26T13:48:57Z

Victor moved page University Hospital for Tumors of Zagreb Trials to University Hospital for Tumours of Zagreb Trials

← Older revision

Revision as of 13:48, 26 August 2024

Victor at 13:48, 26 August 2024

2024-08-26T13:48:50Z

← Older revision		Revision as of 13:48, 26 August 2024
Line 1:		Line 1:
	{{forresearchers}} {{forpatients}} {{forproviders}}		{{forresearchers}} {{forpatients}} {{forproviders}}
	Go back to [[University Hospital for ~~Tumors~~ of Zagreb]] page		Go back to [[University Hospital for Tumours of Zagreb]] page

	'''NCTID''': NCT02562443		'''NCTID''': NCT02562443

Francine at 22:12, 5 May 2024

2024-05-05T22:12:12Z

← Older revision		Revision as of 22:12, 5 May 2024
Line 1:		Line 1:
	{{forresearchers}} {{forpatients}} {{forproviders}}		{{forresearchers}} {{forpatients}} {{forproviders}}

	Go back to [[University Hospital for Tumors of Zagreb]] page		Go back to [[University Hospital for Tumors of Zagreb]] page

Francine at 22:12, 5 May 2024

2024-05-05T22:12:05Z

← Older revision		Revision as of 22:12, 5 May 2024
Line 1:		Line 1:
	{{forresearchers}} {{forpatients}} {{forproviders}}		{{forresearchers}} {{forpatients}} {{forproviders}}

			Go back to [[University Hospital for Tumors of Zagreb]] page

	'''NCTID''': NCT02562443		'''NCTID''': NCT02562443

Francine at 22:11, 5 May 2024

2024-05-05T22:11:29Z

← Older revision		Revision as of 22:11, 5 May 2024
Line 1:		Line 1:
			{{forresearchers}} {{forpatients}} {{forproviders}}

	'''NCTID''': NCT02562443		'''NCTID''': NCT02562443
	'''Title''': [[hasTrialTitle::Controlled Study of Rigosertib Versus Physician’s Choice of Treatment in MDS Patients After Failure of an HMA]]		'''Title''': [[hasTrialTitle::Controlled Study of Rigosertib Versus Physician’s Choice of Treatment in MDS Patients After Failure of an HMA]]

Francine at 13:50, 4 January 2024

2024-01-04T13:50:04Z

← Older revision		Revision as of 13:50, 4 January 2024
Line 1:		Line 1:
	'''NCTID''': NCT02562443		'''NCTID''': NCT02562443
	'''Title''': Controlled Study of Rigosertib Versus Physician’s Choice of Treatment in MDS Patients After Failure of an HMA		'''Title''': [[hasTrialTitle::Controlled Study of Rigosertib Versus Physician’s Choice of Treatment in MDS Patients After Failure of an HMA]]
	'''Study Summary''': The study’s primary objective <math display="block">in a population of patients with MDS after failure of treatment with azacitidine (AZA) or decitabine (DAC)</math>, is to compare the overall survival (OS) of patients in the rigosertib group vs the Physician’s Choice group, in all patients and in a subgroup of patients with IPSS-R very high risk.		'''Study Summary''': The study’s primary objective <math display="block">in a population of patients with MDS after failure of treatment with azacitidine (AZA) or decitabine (DAC)</math>, is to compare the overall survival (OS) of patients in the rigosertib group vs the Physician’s Choice group, in all patients and in a subgroup of patients with IPSS-R very high risk.
	'''Sponsor''': Onconova Therapeutics, Inc.		'''Sponsor''': Onconova Therapeutics, Inc.
Line 9:		Line 9:
	'''Recruitment Status''': TERMINATED		'''Recruitment Status''': TERMINATED
	'''Condition''': Myelodysplastic Syndrome		'''Condition''': Myelodysplastic Syndrome

	'''NCTID''': NCT04736706		'''NCTID''': NCT04736706
	'''Title''': A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)		'''Title''': [[hasTrialTitle::A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)]]
	'''Study Summary''': The goal of this study is to evaluate the efficacy and safety of pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab plus lenvatinib as first-line treatment in participants with advanced clear cell renal cell carcinoma (ccRCC). The primary hypotheses are (1) pembrolizumab plus belzutifan plus lenvatinib is superior to pembrolizumab plus lenvatinib with respect to progression-free survival (PFS) and overall survival (OS), in advanced ccRCC participants; and (2) pembrolizumab/quavonlimab plus lenvatinib is superior to pembrolizumab plus lenvatinib with respect to PFS and OS, in advanced ccRCC participants.		'''Study Summary''': The goal of this study is to evaluate the efficacy and safety of pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab plus lenvatinib as first-line treatment in participants with advanced clear cell renal cell carcinoma (ccRCC). The primary hypotheses are (1) pembrolizumab plus belzutifan plus lenvatinib is superior to pembrolizumab plus lenvatinib with respect to progression-free survival (PFS) and overall survival (OS), in advanced ccRCC participants; and (2) pembrolizumab/quavonlimab plus lenvatinib is superior to pembrolizumab plus lenvatinib with respect to PFS and OS, in advanced ccRCC participants.
	'''Sponsor''': Merck Sharp & Dohme LLC		'''Sponsor''': Merck Sharp & Dohme LLC
Line 19:		Line 20:
	'''Recruitment Status''': RECRUITING		'''Recruitment Status''': RECRUITING
	'''Condition''': Carcinoma, Renal Cell		'''Condition''': Carcinoma, Renal Cell

	'''NCTID''': NCT01339260		'''NCTID''': NCT01339260
	'''Title''': An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting		'''Title''': [[hasTrialTitle::An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting]]
	'''Study Summary''': NETU-08-18 is a two-arm clinical study assessing efficacy and safety of a single oral dose of netupitant and palonosetron, two antiemetic drugs, versus oral palonosetron, both given with oral dexamethasone. The objective of the study is to demonstrate that netupitant and palonosetron are more effective than palonosetron alone, to prevent nausea and vomiting induced by moderately emetogenic cancer chemotherapy after administration of repeated cycles of chemotherapy.		'''Study Summary''': NETU-08-18 is a two-arm clinical study assessing efficacy and safety of a single oral dose of netupitant and palonosetron, two antiemetic drugs, versus oral palonosetron, both given with oral dexamethasone. The objective of the study is to demonstrate that netupitant and palonosetron are more effective than palonosetron alone, to prevent nausea and vomiting induced by moderately emetogenic cancer chemotherapy after administration of repeated cycles of chemotherapy.
	'''Sponsor''': Helsinn Healthcare SA		'''Sponsor''': Helsinn Healthcare SA
Line 29:		Line 31:
	'''Recruitment Status''': COMPLETED		'''Recruitment Status''': COMPLETED
	'''Condition''': Chemotherapy-Induced Nausea and Vomiting		'''Condition''': Chemotherapy-Induced Nausea and Vomiting

	'''NCTID''': NCT00989131		'''NCTID''': NCT00989131
	'''Title''': Study of Paclitaxel in Patients With Ovarian Cancer		'''Title''': [[hasTrialTitle::Study of Paclitaxel in Patients With Ovarian Cancer]]
	'''Study Summary''': RATIONALE: Paclitaxel is one of the most widely used human anticancer agents. Paclitaxel has a low degree of solubility and Cremophor EL is typically used as the solubiliser. Cremophor EL is known to cause hypersensitivity reactions that can be life-threatening. As Paclical® does not contain Cremophor EL, hypersensitivity reactions can be expected to be less. PURPOSE: To study the efficay and safety of two different formulations of paclitaxel, Paclical® and Taxol®.		'''Study Summary''': RATIONALE: Paclitaxel is one of the most widely used human anticancer agents. Paclitaxel has a low degree of solubility and Cremophor EL is typically used as the solubiliser. Cremophor EL is known to cause hypersensitivity reactions that can be life-threatening. As Paclical® does not contain Cremophor EL, hypersensitivity reactions can be expected to be less. PURPOSE: To study the efficay and safety of two different formulations of paclitaxel, Paclical® and Taxol®.
	'''Sponsor''': Oasmia Pharmaceutical AB		'''Sponsor''': Oasmia Pharmaceutical AB
Line 39:		Line 42:
	'''Recruitment Status''': COMPLETED		'''Recruitment Status''': COMPLETED
	'''Condition''': Epithelial Ovarian Cancer		'''Condition''': Epithelial Ovarian Cancer

	'''NCTID''': NCT02668653		'''NCTID''': NCT02668653
	'''Title''': Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)		'''Title''': [[hasTrialTitle::Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)]]
	'''Study Summary''': Quizartinib is an experimental drug. It is not approved for regular use. It can only be used in medical research. Adults might be able to join this study after bone marrow tests show they have a certain kind of blood cancer (FLT3-ITD AML). Participants will have an equal chance of receiving quizartinib or placebo along with their chemotherapy.		'''Study Summary''': Quizartinib is an experimental drug. It is not approved for regular use. It can only be used in medical research. Adults might be able to join this study after bone marrow tests show they have a certain kind of blood cancer (FLT3-ITD AML). Participants will have an equal chance of receiving quizartinib or placebo along with their chemotherapy.
	'''Sponsor''': Daiichi Sankyo, Inc.		'''Sponsor''': Daiichi Sankyo, Inc.
Line 49:		Line 53:
	'''Recruitment Status''': COMPLETED		'''Recruitment Status''': COMPLETED
	'''Condition''': Acute Myeloid Leukemia		'''Condition''': Acute Myeloid Leukemia

	'''NCTID''': NCT04700124		'''NCTID''': NCT04700124
	'''Title''': Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)		'''Title''': [[hasTrialTitle::Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)]]
	'''Study Summary''': The purpose of this study is to assess the antitumor efficacy and safety of perioperative enfortumab vedotin (EV) plus pembrolizumab and radical cystectomy (RC) + pelvic lymph node dissection (PLND) compared with the current standard of care (neoadjuvant chemotherapy <math display="block">gemcitabine plus cisplatin</math> and RC + PLND) for participants with MIBC who are cisplatin-eligible. The primary hypothesis is perioperative EV and pembrolizumab and RC + PLND (Arm A) will achieve superior event free survival (EFS) compared with neoadjuvant gemcitabine + cisplatin and RC + PLND (Arm B).		'''Study Summary''': The purpose of this study is to assess the antitumor efficacy and safety of perioperative enfortumab vedotin (EV) plus pembrolizumab and radical cystectomy (RC) + pelvic lymph node dissection (PLND) compared with the current standard of care (neoadjuvant chemotherapy <math display="block">gemcitabine plus cisplatin</math> and RC + PLND) for participants with MIBC who are cisplatin-eligible. The primary hypothesis is perioperative EV and pembrolizumab and RC + PLND (Arm A) will achieve superior event free survival (EFS) compared with neoadjuvant gemcitabine + cisplatin and RC + PLND (Arm B).
	'''Sponsor''': Merck Sharp & Dohme LLC		'''Sponsor''': Merck Sharp & Dohme LLC